500 mg

O._._um_

4.

:._3.5

:- HCI

:

N N| | - HCI

HNH

1.5

ATP Adenosine triphosphate 3

AGI

BE

bid indie 1

BIG Biganide

CYP P450 P450

DDI Ding-drug

DPP4-I Dipeptidyl peptidase—4 DPP-4

EMA Agency

U.S. Food and

GLIN Glinide

GLP Good practice

GLPl-RA Glucagon-like peptide 1 receptor agonist GLPI

HbAlc HemoglobinAlc Alc

council for of El EUICH technical for pharmaceuticals

for human use

MMRM model repeated

OGTT Oral tolerance test E!

PD Phannacodynamic

PK

from the QTQT of the QRS to the end of

the T wave

QTc QT interval for heart rate QT

SGLTZ-I Sodium glucose 2 inhibitor SGLT2

SU Sulfonylurea

TZD Thiazolidinedione

-‘-

I

L

9'L

1.5

20l-2c. 20.-20.

1.5-3

— -

s

5

5

5 3.1.4.04

5

5 3.1.4.06

5

5

5

5

5 3.1.4.11

5

5

s

1.5

DDI

3.13.1.1

10

5

5

5

5

5

5

5

5 3.3.5.01

5

5

5

5

5

5

5 3.5.1.01

5

pH

‘

: 2 -

15

O._._u

1.6

2021

2.SA

:2021 4 - <

O._._um_

mgmg mg mg mg

mg I mg3 mg

.:

-.

_HHHH_HHI

1.7

5 .

—

10mg25mg

lardiance Tablets 10mg-25mg

BoehringerIngelheim

I:

1 El

E l

I .

1.7 11

1.7

* SGLTZ

‘J

E

‘

'J

-

—|

1.7 23

26.

MS